TPST
What one share of Tempest Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates.
Tempest Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.56 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.33 |
| Cash and investments | $0.05 |
| Book value | −$0.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $1.12 | −$321.81 | $0.02 | −$77.41 | — | −$530.53 |
| 2018 | — | −$17.58 | $0.02 | −$15.31 | $0.00 | — |
| 2019 | — | −$3.25 | $0.03 | −$3.04 | $0.00 | −$2.76 |
| 2020 | — | −$41.03 | $0.11 | −$40.73 | $0.00 | −$130.47 |
| 2021 | — | −$7.47 | $0.04 | −$6.88 | — | $5.23 |
| 2022 | — | −$3.09 | $0.05 | −$2.74 | — | $1.72 |
| 2023 | — | −$1.91 | $0.01 | −$1.79 | — | $1.21 |
| 2024 | — | −$19.50 | $0.20 | −$15.59 | — | $5.65 |
| 2025 | — | −$6.33 | $0.00 | −$6.46 | — | $1.35 |